Doctor Genmin Lu
Portola Pharmaceuticals Inc, South San Francisco (United States of America)
Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI)
Event: ESC Congress 2018
Topic: Thrombosis, Bleeding
Session: Platelets, haemostasis and coagulation
ESC 365 is supported by
